Gut-homing lymphocytes that express the integrin α4β7 and CCR9 might contribute to development of primary sclerosing cholangitis (PSC). Vedolizumab, which blocks the integrin α4β7, is used to treat patients with inflammatory bowel diseases (IBD), but there are few data on its efficacy in patients with PSC. We investigated the effects of vedolizumab in a large international cohort of patients with PSC and IBD.
Effects of Vedolizumab in Patients with Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases / Lynch, Kate D; Chapman, Roger W; Keshav, Satish; Montano-Loza, Aldo J; Mason, Andrew L; Kremer, Andreas E; Vetter, Marcel; de Krijger, Manon; Ponsioen, Cyriel Y; Trivedi, Palak; Hirschfield, Gideon; Schramm, Christoph; Liu, Chung Heng; Bowlus, Christopher L; Estes, Derek J; Pratt, Daniel; Hedin, Charlotte; Bergquist, Annika; de Vries, Annemarie C; Janneke van der Woude, C; Yu, Lei; Assis, David N; Boyer, James; Ytting, Henriette; Hallibasic, Emina; Trauner, Michael; Marschall, Hanns-Ulrich; Daretti, Luigi M; Marzioni, Marco; Yimam, Kidist K; Perin, Nicola; Floreani, Annarosa; Beretta-Piccoli, Benedetta Terziroli; Rogers, Jennifer K; Levy, Cynthia. - In: CLINICAL GASTROENTEROLOGY AND HEPATOLOGY. - ISSN 1542-3565. - (2020). [10.1016/j.cgh.2019.05.013]
Effects of Vedolizumab in Patients with Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases
Daretti, Luigi M
;Marzioni, Marco
;
2020-01-01
Abstract
Gut-homing lymphocytes that express the integrin α4β7 and CCR9 might contribute to development of primary sclerosing cholangitis (PSC). Vedolizumab, which blocks the integrin α4β7, is used to treat patients with inflammatory bowel diseases (IBD), but there are few data on its efficacy in patients with PSC. We investigated the effects of vedolizumab in a large international cohort of patients with PSC and IBD.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
